Susan Galbraith, AstraZeneca EVP, oncology R&D
Spotting a gem from transpacific biotech, AstraZeneca pays $25M cash to pick up a preclinical bispecific antibody
Looking to expand its oncology pipeline, AstraZeneca has turned to the east to pick up a next-gen drug against an emerging target.
Harbour BioMed, a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
